StockData
Abbott Laboratories logo

Abbott Laboratories (ABT) operating KPIs

ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)

Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%

Abbott Laboratories molecular Diagnostics — U.S. COVID-19 Testing Sales ($M) ($M)

Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A

Latest, Q4 2024
1
Period ended Dec 31, 2024
Change on a year earlier
-80.0%
5 in Q4 2023
History
13 quarters
Since Q4 2021
Sources
9
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedMolecular Diagnostics — U.S. COVID-19 Testing Sales ($M) ($M)Year on yearSource
Q4 2024Dec 31, 20241-80.0%SEC Filing (0001628280-25-002092) ↗
Q3 2024Sep 30, 20242-60.0%SEC Filing (0001628280-24-042893) ↗
Q2 2024Jun 30, 20242-50.0%SEC Filing (0001628280-24-032182) ↗
Q1 2024Mar 31, 20243-70.0%SEC Filing (0001628280-24-016497) ↗
Q4 2023Dec 31, 20235-70.6%SEC Filing (0001628280-25-002092) ↗
Q3 2023Sep 30, 20235-80.8%SEC Filing (0001628280-24-042893) ↗
Q2 2023Jun 30, 20234-88.2%SEC Filing (0001628280-24-032182) ↗
Q1 2023Mar 31, 202310-91.2%SEC Filing (0001628280-24-016497) ↗
Q4 2022Dec 31, 202217-80.9%SEC Filing (0001628280-24-002009) ↗
Q3 2022Sep 30, 202226–SEC Filing (0001628280-23-034544) ↗
Q2 2022Jun 30, 202234–SEC Filing (0001628280-23-025156) ↗
Q1 2022Mar 31, 2022114–SEC Filing (0001628280-23-012020) ↗
Q4 2021Dec 31, 202189–SEC Filing (0001628280-23-001516) ↗

Cite this data

StockData. (2026). Abbott Laboratories Molecular Diagnostics — U.S. COVID-19 Testing Sales ($M) ($M), quarterly Q4 2021–Q4 2024 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/dx-mol-covid-us

See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.